MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.870
-0.010
-0.53%
Opening 13:13 10/22 EDT
OPEN
1.890
PREV CLOSE
1.880
HIGH
1.940
LOW
1.790
VOLUME
81.95K
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
0.7550
MARKET CAP
19.44M
P/E (TTM)
-1.3412
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it has now completed enrollment in its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. “Completing enrollment is a significant milestone and comes at a time when we are seeing a new wave if infections in certain geographies and an increased focus on developing therapies to treat COVID-19,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. “While the virus presents significant danger overall, the vast majority of people testing positive for COVID-19 do not require hospitalization and instead quarantine at home while they manage their symptoms and attempt not to infect those around them. As there are no currently FDA-approved treatments to help these patients, we are developing AT-301 for at home use so that they can recover faster.”Atossa plans to identify potential partners who are developing COVID-19 diagnostic tests so that AT-301 nasal spray may be co-developed and commercialized with the goal of making the AT-301 therapy available at the time a person tests positive for the coronavirus. Atossa also plans to develop its nasal spray to potentially help prevent COVID-19 infection -- particularly for people in high risk environments -- including, for example, people living with a patient infected with COVID-19, healthcare workers, emergency responders and teachers. In addition to seeking a partner, next steps with this program include contracting for a commercial supply of the nasal spray devices; reporting preliminary top line results from the Phase 1 study; and completing regulatory filings and any necessary approvals to launch a Phase 2 study, which we are planning for the first half of 2021.The ongoing Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. The study is being conducted in Australia.About Atossa TherapeuticsAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.comForward-Looking StatementsForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and General Counsel Office: (866) 893-4927 kyle.guse@atossainc.comInvestor Relations Contact: Core IR Office:(516) 222-2560 ir@atossainc.comSource: Atossa Therapeutics, Inc.
GlobeNewswire · 3d ago
Atossa Therapeutics Completes Enrollment Of Phase 1 Clinical Study Of AT-301 Nasal Spray Being Developed For Coronavirus
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc.
Benzinga · 3d ago
Registration Is Now Open For Atossa Therapeutics Tribe Public Webinar Presentation and Q&A Event On October 13, 2020
In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast cancer”SEATTLE, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc
GlobeNewswire · 10/07 14:30
Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family
Renowned physician-scientist Dr. Steven Quay, MD, PhD, and CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) has provided 50 copies of his best-selling book, "Stay Safe: a Physician's Guide to Survive Coronavirus" to the White House following the news that President Trump and the First Lady
PR Newswire · 10/02 14:20
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020
SEATTLE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces CEO Dr.
GlobeNewswire · 09/21 22:09
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study ArmSEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with
GlobeNewswire · 09/17 14:30
Atossa's COVID-19 nasal spray receives second positive safety review
Atossa Therapeutics ([[ATOS]] +14.7%) has announced a positive interim safety assessment from the second cohort of 8 healthy participants in Phase 1 study of AT-301 administered by nasal spray, for
Seekingalpha · 09/17 13:46
Atossa Genetics Reports Receives Second Positive Interim Safety Assessment In Study Of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer
Benzinga · 09/17 13:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATOS stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 324.37K
% Owned: 3.12%
Shares Outstanding: 10.40M
TypeInstitutionsShares
Increased
1
700
New
6
58.46K
Decreased
1
1.81K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.40%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATOS
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.